.Nature Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a typical consequence of 11 months, people along with metastatic stomach lumps that received biomarker-matched therapies based on distributing tumor DNA profiling revealed a higher scientific perk than those obtaining unmatched therapy.